Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 7, 2024.

Enterprise Value to FCFF (EV/FCFF)

Microsoft Excel

Free Cash Flow to The Firm (FCFF)

Moderna Inc., FCFF calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net income (loss)
Net noncash charges
Changes in assets and liabilities, net of acquisition of business
Net cash provided by (used in) operating activities
Cash paid for interest, net of tax1
Purchases of property, plant and equipment
Right-of-use assets obtained in exchange for financing lease liabilities
Free cash flow to the firm (FCFF)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Operating Activities Cash Flow
The net cash provided by operating activities displayed significant variation over the five-year period. In 2019, there was a negative cash flow of $459 million, indicating operational cash outflow. A notable turnaround occurred in 2020 with a positive cash inflow of $2,027 million, which then surged markedly in 2021 to $13,620 million. This peak was followed by a decline to $4,981 million in 2022, and subsequently a reversal to a negative cash flow of $3,118 million in 2023. This trend suggests substantial volatility in operating cash generation, with a peak in 2021 followed by deteriorating cash flow performance in the later years.
Free Cash Flow to the Firm (FCFF)
The free cash flow to the firm mirrored the trend observed in operating cash flow. Starting with a negative outflow of $485 million in 2019, FCFF turned positive in 2020 at $1,966 million and reached a high of $13,223 million in 2021. However, this was followed by a reduction to $3,826 million in 2022 and a further decline into negative territory at -$3,794 million in 2023. The pattern indicates that after a very strong cash generation phase reaching its apex in 2021, the firm experienced significant cash flow pressures, ultimately resulting in negative free cash flow by 2023.
Overall Cash Flow Analysis
The data reveal a cyclical pattern with considerable fluctuations in cash flow metrics over the period. Both operating cash flow and FCFF demonstrate a recovery from negative values in 2019 to peak levels in 2021, likely reflecting successful operational performance or capital deployment during this time. The subsequent downturn leading into negative figures in 2023 points to emerging challenges in sustaining cash flow and may indicate increased operational costs, investment outlays, or changes in working capital dynamics adversely impacting liquidity. The sharp decline post-2021 warrants further examination of underlying factors affecting cash inflows and outflows to understand the drivers of this deterioration.

Interest Paid, Net of Tax

Moderna Inc., interest paid, net of tax calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Effective Income Tax Rate (EITR)
EITR1
Interest Paid, Net of Tax
Cash paid for interest, before tax
Less: Cash paid for interest, tax2
Cash paid for interest, net of tax

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 See details »

2 2023 Calculation
Cash paid for interest, tax = Cash paid for interest × EITR
= × =

The effective income tax rate (EITR) demonstrates a fluctuating trend over the five-year period. Beginning with no recorded value in 2019, the rate was 21% in 2020, followed by a significant decrease to 8.1% in 2021. In 2022, the rate rose moderately to 12.7%, and then increased again to 21% in 2023, returning to the level observed in 2020. This variability indicates changes in tax planning, profitability by jurisdiction, or tax regulation impacts during these years.

The cash paid for interest, net of tax, shows a consistent upward trend. Starting at $6 million in 2019, the amount increased to $7 million in 2020, nearly doubled to $13 million in 2021, then rose further to $22 million in 2022, and reached $31 million in 2023. This steady increase suggests growing debt levels or rising interest rates impacting the company's financing costs over the period reviewed.

Effective Income Tax Rate (EITR)
Absent in 2019; peaked at 21% in 2020; declined sharply to 8.1% in 2021; rose to 12.7% in 2022; returned to 21% in 2023.
Cash Paid for Interest, Net of Tax (US$ in millions)
Increased progressively from $6 million in 2019 to $31 million in 2023, marking more than a fivefold rise during the period.

Enterprise Value to FCFF Ratio, Current

Moderna Inc., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV)
Free cash flow to the firm (FCFF)
Valuation Ratio
EV/FCFF
Benchmarks
EV/FCFF, Competitors1
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences
EV/FCFF, Industry
Health Care

Based on: 10-K (reporting date: 2023-12-31).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

Moderna Inc., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Enterprise value (EV)1
Free cash flow to the firm (FCFF)2
Valuation Ratio
EV/FCFF3
Benchmarks
EV/FCFF, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences
EV/FCFF, Industry
Health Care

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 See details »

2 See details »

3 2023 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =

4 Click competitor name to see calculations.

The financial data exhibits significant fluctuations over the analyzed period. Key trends and insights are as follows:

Enterprise Value (EV)
The enterprise value showed a substantial increase from 8,579 million USD at the end of 2019 to a peak of 57,415 million USD at the end of 2020. Subsequently, it declined steadily over the following years, reaching 28,826 million USD by the end of 2023. This pattern indicates a rapid growth phase followed by a contraction in market valuation or enterprise worth during the later period.
Free Cash Flow to the Firm (FCFF)
The free cash flow to the firm improved markedly from a negative value of -485 million USD at the end of 2019 to a positive 1,966 million USD in 2020. It then surged significantly to 13,223 million USD by the end of 2021, showing a strong generation of cash flows. However, this was followed by a sharp decrease to 3,826 million USD in 2022, and the cash flow turned negative again at -3,794 million USD by the end of 2023. This instability suggests challenges in maintaining consistent positive cash flow after the peak period.
EV to FCFF Ratio
This valuation ratio was not reported for 2019 and 2023 but shows important dynamics during the intermediate years. It was particularly elevated in 2020 at 29.2, implying a high enterprise value relative to free cash flow, possibly indicating a premium or market optimism. The ratio decreased substantially in 2021 to 3.86, reflecting a more favorable valuation in terms of cash flow generation. However, it rose again in 2022 to 11.76, indicating a less attractive valuation compared to the free cash flow at that time. The absence of this ratio in 2023 coincides with negative free cash flow, precluding meaningful calculation.

Overall, the data reflect a period of rapid growth and high valuation up to 2021, followed by declining enterprise value and experiencing volatility in cash flow generation. The resurgence of negative free cash flow and decreased enterprise value in 2023 might highlight emerging financial pressures or market corrections. These trends warrant thorough examination for potential operational or market-driven factors impacting financial performance and valuation.